FDA safety labeling changes: PROVAYBLUE (methylene blue) – serotonin syndrome with serotonergic drugs and opioids (2023)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · 2023

U.S. Food et al., 2023: FDA safety-labeling-change record for the 2023 boxed warning adding opioids to the serotonin-syndrome warning for methylene blue.

PROVAYBLUE® may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids.

U.S. Food et al., 2023: FDA safety-labeling-change record for the 2023 boxed warning adding opioids to the serotonin-syndrome warning for methylene blue. Application 204630, supplement 22, approved drug label at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204630s022lbl.pdf. The record states "Some of the reported cases were fatal." Recorded under F5 against the source's "rare/manageable/celebrate" framing. Study type: regulatory record.